Emerging role of pharmacogenomics in heart failure

Current Opinion in Cardiology

Volumn 23, Issue 3, 2008, Pages 261-268

  McNamara, Dennis M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Aldosterone synthase; Beta adrenergic receptors; Clinical trials; Genetics; Heart failure; Race

Indexed keywords

ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ARGININE; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDRALAZINE; ISOSORBIDE DINITRATE; METOPROLOL SUCCINATE; SPIRONOLACTONE;

AFRICAN AMERICAN; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HEART FAILURE; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; PHARMACOGENOMICS; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SURVIVAL; TREATMENT OUTCOME;

AFRICAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC HETEROGENEITY; GENOTYPE; HEART FAILURE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 41749117082     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3282fcd662     Document Type: Review

References (42)

1. McNamara DM, MacGowan GA, London B. Clinical importance of beta receptor polymorphisms in cardiovascular disease. Am J Pharamcogenomics 2001; 2:73-78.
2. Feldman DS, Carnes CA, Abraham WT, et al. Mechanisms of disease β-adrenergic receptors - alternations in signal transduction and pharmacogenomics in heart failure. Cardio Med 2005; 2:475-483.
3. The BEST Investigators. A trial of the beta blocker bucindolol in patients with advanced chronic heart failure. New Engl J Med 2001; 344:1659-1667.
4. 1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. PNAS 2006; 103:11288-11293. This analysis from the BEST trial demonstrates an increased impact of the β-blocker bucindolol in patients with the Arg389Arg genotype. This is the largest pharmacogenetic study to prospectively investigate the impact of β-receptor genotype on a randomized clinical study of β-blockade.
5. Hjalmarson A, Goldstein S, Fagerberg B, et al. The effects of controlled release metoprolol on total mortality, hospitalizations and well being in patients with heart failure (MERIT-HF). JAMA 2000; 283:1295-1302.
6. White H, deBoer RA, Maqbool A, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. Eur J Heart Fail 2003; 5:463-468.
7. 1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharm and Geno 2007; 17:941-949. This retrospective analysis suggests chronic heart failure patients with the Arg389Arg genotype had a greater increase in LVEF on carvedilol. This study provides functional data that support to role or the Arg389 genotype in targeting β-blocker response.
8. Muthumala A, Drenos F, Elliott PM, et al. Role of β adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. Eur J Heart Fail 2008; 10:3-13.
9. Börjesson M, Magnusson Y, Hjalmarson A, et al. A novel polymorphism in the gene coding for the beta (1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000; 21:1853-1858.
10. 2 polymorphisms and the therapeutic response to β receptor agonists and antagonists.
11. 1-adrenergic receptor is associated with effective β-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther 2005; 78:221-231.
12. Johnson JA, Zineh I, Puckett BJ, et al. Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74:44-52.
13. 2 genotype influences heart failure outcomes, and found that the Arg16Gln27 haplotype increased the risk of death or transplantation.
14. 2-adrenoreceptor gene variants on cardiac cavity size and systolic function in idiopathic dilated cardiomyopathy. Pharma J 2007; 7:339-345.
15. Small KM, Wagoner LE, Levin AM, et al. Synergistic polymorphisms of beta1-and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347:1135-1142.
16. 1Arg389Arg genotype in patients with heart failure. This study illustrates that polygenic interactions of functional variants must be understood to fully utilize pharmacogenomics.
17. Andersson B, Sylven C. The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure. J Am Coll Cardiol 1996; 28:162-167.
18. Palmer BR, Pilbrow AP, Yandle TG, et al. Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol 2003; 41:729-736.
19. McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta blocker therapy and the angiotensin converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001; 103:1644-1648.
20. McNamara DM, Holubkov R, Postava L, et al. Phamacogenetic interactions between ACE inhibitor therapy and the Angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol 2004; 44:2019-2026.
21. Bleumink GS, Schut AFC, Sturkenboom MCJM, et al. Mortality in patients with hypertension on angiotensin-1 converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/deletion polymorphism. Pharma Gen 2005; 15:75-81.
22. Tang WHW, Vagelos RH, Yee YG, et al. Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure. Am Heart J 2004; 148:889-894.
23. Ulgen MS, Ozturk O, Alan S, et al. The relationship between angiotensin-converting enzyme (insertion/deletion) gene polymorphism and left ventricular remodeling in acute myocardial infarction. Coron Artery Dis 2007; 18:153-157.
24. Bhatnagar V, O'Connor DT, Schork NJ, et al. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens 2007; 25:2082-2092.
25. Su X, Lee L, Li X, et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circ J Am Heart Assoc 2007; 115:725-732.
26. Pilbrow AP, Palmer BR, Frampton CM, et al. Angiotensinogen M235T and T174M gene polymorphisms in combination doubles the risk of mortality in heart failure. J Am Heart Assoc Hyper 2007; 49:322-327.
27. Li Y, Zagato L, Kuznetsova T, et al. Angiotensin-converting enzyme I/D and a-adducin Gly460Trp polymorphisms. Hyper 2007; 49:1291-1297.
28. Materson BJ. Variability in response to antihypertensive drugs. Am J Med 2007; 120 (4 Suppl 1):S10-S20.
29. Tiago AD, Badenhorst D, Skudicky D, et al. An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovasc Res 2002; 54:584-589.
30. McNamara DM, Tam SW, Sabolinski ML, et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure. J Am Coll Cardiol 2006; 48:1277-1282. This investigation from the AHeFT trial is the first to suggest that aldosterone synthase genotype influences outcomes in patients with chronic heart failure. This is also one of the first reports of pharmacogenetic interaction specifically in a randomized study of African American patients with heart failure.
31. Biolo A, Chao T, Duhaney TAS, et al. Usefulness of the aldosterone synthase gene polymorphism C-344-T to predict cardiac remodeling in African-Americans versus non-African-Americans with chronic systolic heart failure. Am J Cardiol 2007; 100:285-290. This single center study demonstrates the impact of aldosterone synthase genotype on remodeling and supports the functional basis of its impact on heart failure outcomes and therapeutics.
32. Yu HM, Lin SG, Liu GZ, et al. Associations between CYP11B2 gene polymorphisms and the response to angiotensin-converting enzyme inhibitors. Clin Pharmacol Ther 2006; 79:589-599.
33. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med 1986; 314:1547-1552.
34. Carson P, Ziesche S, Johnson G, Cohn JN, for the Vasodilator-Heart Failure trial Study Group. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure Trials. J Card Fail 1999; 5:178-187.
35. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-310.
36. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. New Engl J Med 2004; 351:2049-2057.
37. Siffert W, Rosskopf D, Siffert G, et al. Association of a human G-protein subunit variant with hypertension. Nat Genet 1998; 18:45-48.
38. Sagnella GA. Why is plasma renin activity lower in populations of African origin? J Hum Hypertens 2001; 15:17-25.
39. 298 variant of endothelial nitric oxide synthase: effect on survival for patients with congestive heart failure. Circulation 2003; 107:1598-1602.
40. Rampersaud E, Damcott CM, Fu M, et al. Identification of novel candidate genes for type 2 diabetes from a genome-wide association scan in the Old Order Amish: evidence for replication from diabetes-related quantitative traits and from independent populations. Diabetes 2007; 56:3053-3062.
41. Kathiresan S, Manning AK, Demissie S, . A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet 2007; 8 (Suppl 1):S17.
42. O'Donnell CJ, Cupples LA, D'Agostino RB, et al. Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study. BMC Med Genet 2007; 8 (Suppl 1):S4.